Zura Bio Limited (ZURA)
| Market Cap | 160.86M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -69.24M |
| Shares Out | 43.59M |
| EPS (ttm) | -2.09 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,009,241 |
| Open | 3.600 |
| Previous Close | 3.130 |
| Day's Range | 3.360 - 3.910 |
| 52-Week Range | 2.000 - 14.000 |
| Beta | 0.54 |
| Analysts | Strong Buy |
| Price Target | 16.50 (+347.15%) |
| Earnings Date | May 12, 2024 |
About ZURA
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for ZURA stock is "Strong Buy." The 12-month stock price forecast is $16.5, which is an increase of 347.15% from the latest price.
News
Zura Bio Announces Oversubscribed $112.5 Million Private Placement
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammator...
Zura Bio Announces Robert Lisicki as CEO and Director
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and infla...
Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer
HENDERSON, Nev--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflam...
Zura Bio Announces Participation at March Conferences
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio announces participation at three March conferences.
Zura Bio Announces Participation at February Investor Conferences
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio today announced participation at several upcoming conferences in February.
Zura Bio Continues to Strengthen Leadership with Appointment of Robert Lisicki as President and Kiran Nistala as CMO
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Announces Appointment of Robert Lisicki as President and Dr. Kiran Nistala as CMO.
Zura Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Dermatology Summit
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Dermatology Summit.
Zura Bio Announces Two Immunology Abstracts Presented at the World Allergy Congress in Bangkok
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio announces two immunology abstracts presented at World Allergy Congress (WAC) for ZB-168 and ZB-880.
Zura Bio Appoints Arnout Ploos van Amstel to its Board of Directors
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) announced Arnout Ploos van Amstel has been appointed to its Board of Directors.
Zura Bio Reports Third Quarter 2023 Financial Results and Recent Business Highlights
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune a...
Zura Bio Enters into Sponsored Research Agreement with Benaroya Research Institute
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune ...
Zura Bio Reports Second Quarter 2023 Financial Results and Recent Business Highlights
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a multi-asset clinical-stage biotechnology company focused on developing novel medi...
Zura Bio to Join the Russell 2000® and Russell 3000® Indexes
SAN DIEGO--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio will be added to the Russell 2000® and Russell 3000® Indexes effective after the US market opens on June 26, 2023.
Zura Bio Completes Approximately $80 Million Financing with the Focus on Advancing ZB-106, a Potential First-in-class Anti-IL-17 and Anti-BAFF Dual Antagonist
SAN DIEGO--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: “ZURA”) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and ...
Zura Bio Announces $80 Million Financing and the Licensing of Tibulizumab (ZB-106), a Potential First-in-Class anti-IL-17 and anti-BAFF Dual Antagonist for Autoimmune Diseases
SAN DIEGO--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: “ZURA”) (“Zura” or “Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for i...
Zura Bio Announces Appointment of Chief Scientific Officer
SAN DIEGO--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited announces the appointment of Michael D. Howell, Ph.D., to the role of Chief Scientific Officer and Head of Translational Science.
Zura Bio Limited Announces Closing of Business Combination with JATT Acquisition Corp
SAN DIEGO--(BUSINESS WIRE)--Zura Bio Limited (“Zura”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced t...
JATT Acquisition Corp Shareholders Approve Proposed Business Combination with Zura Bio Limited
LONDON--(BUSINESS WIRE)--JATT Acquisition Corp (NYSE: JATT) (“JATT”), a publicly traded special purpose acquisition company, today announced that its shareholders voted to approve its proposed busines...